Perceptive Advisors LLC Purchases New Stake in Adaptive Biotechnologies Corporation $ADPT

Perceptive Advisors LLC bought a new position in shares of Adaptive Biotechnologies Corporation (NASDAQ:ADPT) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 152,500 shares of the company’s stock, valued at approximately $2,117,000.

Several other hedge funds and other institutional investors have also modified their holdings of ADPT. California State Teachers Retirement System grew its stake in Adaptive Biotechnologies by 1.0% in the 2nd quarter. California State Teachers Retirement System now owns 98,321 shares of the company’s stock valued at $1,145,000 after buying an additional 933 shares during the last quarter. PNC Financial Services Group Inc. lifted its position in Adaptive Biotechnologies by 6.8% during the first quarter. PNC Financial Services Group Inc. now owns 14,737 shares of the company’s stock worth $205,000 after acquiring an additional 941 shares during the last quarter. Captrust Financial Advisors boosted its holdings in shares of Adaptive Biotechnologies by 7.6% during the second quarter. Captrust Financial Advisors now owns 15,762 shares of the company’s stock worth $184,000 after acquiring an additional 1,119 shares during the period. Assetmark Inc. boosted its holdings in shares of Adaptive Biotechnologies by 46.4% during the first quarter. Assetmark Inc. now owns 4,421 shares of the company’s stock worth $61,000 after acquiring an additional 1,401 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. grew its position in shares of Adaptive Biotechnologies by 26.0% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,419 shares of the company’s stock valued at $120,000 after purchasing an additional 1,532 shares during the last quarter. Institutional investors own 99.17% of the company’s stock.

Key Adaptive Biotechnologies News

Here are the key news stories impacting Adaptive Biotechnologies this week:

• Positive Sentiment: Adaptive raised its 2026 MRD revenue outlook to $268 million-$278 million and outlined plans to separate the MRD business. Management and analysts view the transaction as a potential way to create a focused, higher-growth “pure-play” company and unlock shareholder value. Adaptive outlines MRD separation plan while raising 2026 MRD revenue guidance
• Positive Sentiment: Second-quarter revenue was approximately $71.6 million, above the roughly $65.4 million consensus estimate and up 21.5% year over year. Zacks also reported an adjusted loss of $0.10 per share, narrower than the expected $0.13 loss and the $0.17 loss in the prior-year quarter. Adaptive Biotechnologies Reports Q2 Loss, Beats Revenue Estimates
• Positive Sentiment: Analysts raised their targets after the results: TD Cowen increased its target to $28 and maintained a Buy rating, while BTIG lifted its target to $25 and also retained a Buy rating. Analyst price-target coverage
• Neutral Sentiment: Zacks noted that ADPT’s 52-week-high performance reflects improving fundamentals, but investors must assess whether revenue growth, margins and the MRD separation can support additional appreciation. Adaptive Biotechnologies Hit a 52 Week High
• Negative Sentiment: Morgan Stanley raised its target only to $22 and kept an Equal Weight rating, implying limited upside at recent trading levels. The company remains unprofitable, and reported GAAP results included a larger-than-consensus quarterly loss, highlighting ongoing execution and profitability risks.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on ADPT shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research note on Friday, July 17th. BTIG Research boosted their price target on Adaptive Biotechnologies from $24.00 to $25.00 and gave the company a “buy” rating in a research note on Thursday. Morgan Stanley upped their price objective on Adaptive Biotechnologies from $20.00 to $22.00 and gave the company an “equal weight” rating in a report on Thursday. Guggenheim lifted their target price on Adaptive Biotechnologies from $22.00 to $25.00 and gave the stock a “buy” rating in a report on Thursday. Finally, JPMorgan Chase & Co. dropped their target price on Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating for the company in a report on Wednesday, May 6th. Five research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $23.33.

Adaptive Biotechnologies Trading Down 6.7%

Shares of ADPT stock opened at $22.57 on Friday. The company has a current ratio of 4.79, a quick ratio of 3.22 and a debt-to-equity ratio of 2.22. The stock has a market cap of $3.61 billion, a P/E ratio of -55.05 and a beta of 2.07. The stock has a 50 day simple moving average of $19.43 and a 200 day simple moving average of $16.66. Adaptive Biotechnologies Corporation has a 1 year low of $9.96 and a 1 year high of $24.57.

Adaptive Biotechnologies (NASDAQ:ADPT) last posted its quarterly earnings data on Tuesday, July 28th. The company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.12). The company had revenue of $71.55 million for the quarter, compared to the consensus estimate of $65.44 million. Adaptive Biotechnologies had a negative return on equity of 36.81% and a negative net margin of 20.73%.Adaptive Biotechnologies’s revenue was up 21.5% on a year-over-year basis. During the same quarter last year, the business earned ($0.17) EPS. On average, research analysts predict that Adaptive Biotechnologies Corporation will post -0.43 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Harlan S. Robins sold 492,400 shares of the firm’s stock in a transaction on Tuesday, July 21st. The stock was sold at an average price of $21.89, for a total value of $10,778,636.00. Following the transaction, the insider owned 812,058 shares in the company, valued at approximately $17,775,949.62. This trade represents a 37.75% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Francis Lo sold 44,838 shares of the business’s stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $22.59, for a total value of $1,012,890.42. Following the completion of the transaction, the insider directly owned 230,713 shares of the company’s stock, valued at approximately $5,211,806.67. This trade represents a 16.27% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 1,305,787 shares of company stock valued at $27,828,563. Company insiders own 5.70% of the company’s stock.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.